| Item type |
デフォルトアイテムタイプ（フル）(1) |
| 公開日 |
2025-02-26 |
| タイトル |
|
|
タイトル |
Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells |
|
言語 |
en |
| 作成者 |
石川,拓郎
大崎,智弘
Sugiura,Akihiro
Tashiro,Jiro
Warita,Tomoko
Hosaka,Yoshinao Z.
割田,克彦
|
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
The epithelial-to-mesenchymal transition (EMT) is fundamental in cancer progression and contributes to the acquisition of malignant properties. The statin class of cholesterol-lowering drugs exhibits pleiotropic anticancer effects in vitro and in vivo, and many epidemiologic studies have reported a correlation between statin use and reduced cancer mortality. We have shown previously that sensitivity to the anti-proliferative effect of statins varies among human cancer cells and statins are more effective against mesenchymal-like cells than epithelial-like ones in human cancers. There have only been few reports on the application of statins to cancer therapy in veterinary medicine, and differences in statin sensitivity among canine cancer cells have not been examined. In this study, we aimed to clarify the correlation between sensitivity to atorvastatin and epithelial/mesenchymal states in 11 canine cancer cell lines derived from mammary gland, squamous cell carcinoma, lung, and melanoma. Sensitivity to atorvastatin varied among canine cancer cells, with IC50 values ranging from 5.92 to 71.5 μM at 48 h, which were higher than the plasma concentrations clinically achieved with statin therapy. Atorvastatin preferentially attenuated the proliferation of mesenchymal-like cells. In particular, highly statin-sensitive cells were characterized by aberrant expression of the ZEB family of EMT-inducing transcription factors. However, ZEB2 silencing in highly sensitive cells did not induce resistance to atorvastatin. Taken together, these results suggest that high expression of ZEB is a characteristic of highly statin-sensitive cells and could be a molecular marker for predicting whether cancers are sensitive to statins, though ZEB itself does not confer statin sensitivity. |
|
言語 |
en |
| 出版者 |
|
|
出版者 |
Wiley |
|
言語 |
en |
| 日付 |
|
|
日付 |
2021-10-17 |
|
日付タイプ |
Issued |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
| 関連情報 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1111/vco.12778 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
14765829 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
14765810 |
| 収録物名 |
|
|
収録物名 |
Veterinary and comparative oncology |
|
言語 |
en |
| 巻 |
|
|
巻 |
20 |
| 号 |
|
|
号 |
1 |
| ページ数 |
|
|
ページ数 |
11 |
| 開始ページ |
|
|
開始ページ |
313 |
| 終了ページ |
|
|
終了ページ |
323 |
| 書誌情報 |
en : Veterinary and comparative oncology
巻 20,
号 1,
p. 313-323,
ページ数 11,
発行日 2021-10-17
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
言語 |
en |
|
権利情報 |
This is the peer reviewed version of the following article: Ishikawa T, Osaki T, Sugiura A, et al. Atorvastatin preferentially inhibits the growth of high ZEB-expressing canine cancer cells. Vet Comp Oncol. 2022; 20(1): 313-323., which has been published in final form at doi:10.1111/vco.12778. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. |
vco20_313.pdf (4.8 MB)
